logo-loader
viewArix Bioscience PLC

Arix Bioscience portfolio company Amplyx Pharmaceuticals raises US$53mln

New investors in Amplyx include Pfizer and Adage Capital

xxxxxxx

Arix Bioscience PLC (LON:ARIX) said its portfolio company, Amplyx Pharmaceuticals, has closed a US$53mln Series C ‘extension’ fundraising round, taking the total to US$90mln

New investors included Pfizer and Adage Capital. UK-listed venture capital company Arix has a 3% stake worth US$6.4mln.  

Amplyx will use the cash injection to develop fosmanogepix (APX001) and MAU868 for the treatment of life-threatening fungal infections and BK Virus.

Jeffries added that Amplyx's Series C extension expands that company's runway and also reaffirms its valuation and potential.

The broker reiterated its buy, saying as its private portfolio is incrementally de-risked and validated; the current 49% discount provides a cheap entry with various catalysts ahead.

"Events like this can assuage investor concerns over private values and funding."

The broker estimates Arix's current NAV at 161p or a 49% discount to today's share price of 81.5p.

 

-- adds comment, share price --

 

Quick facts: Arix Bioscience PLC

Price: 87 GBX

LSE:ARIX
Market: LSE
Market Cap: £117.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience PLC: Proactive One2One Virtual Event

Arix Bioscience PLC's (LON:ARIX) Jonathan Tobin pitches the company to investors at the Proactive One2One Virtual Event. Arix is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

3 weeks, 5 days ago

2 min read